LabCorp

Patient Report

Specimen ID: 297-298-1445-0
Control ID: B0082220747

Acct #: 09018260 Phone: (813) 498-1070 Rte: 00

[redacted]

4PMD
4910 E Adamo Dr Unit B
TAMPA FL 33605

Patient Details
DOB: 02/27/1978
Age(y/m/d): 040/07/27
Gender: M SSN:
Patient ID: [redacted]

Specimen Details
Date collected: 10/24/2018 0918 Local
Date received: 10/25/2018
Date entered: 10/25/2018
Date reported: 11/01/2018 0831 ET

Physician Details
Ordering: R MCCLAIN
Referring:
ID: 15759893
NPI: 1487804308

General Comments & Additional Information
Clinical Info: [redacted]

Alternate Control Number: B0082220747
Total Volume: Not Provided

Alternate Patient ID: Not Provided
Fasting: Yes

Ordered Items
CBC With Differential/Platelet; Comp. Metabolic Panel (14); Lipid Panel w/ Chol/HDL Ratio; Testosterone, Free+Total LC/MS; Dihydrotestosterone; Thyroxine (T4) Free, Direct, S; DHEA-Sulfate; TSH; Prolactin; Prostate-Specific Ag, Serum; IGF-1; Estradiol, Sensitive; Triiodothyronine (T3), Free; Sex Horm Binding Glob, Serum; Venipuncture

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
CBC With Differential/Platelet					
WBC	4.1		x10E3/uL	3.4 - 10.8	01
RBC	5.17		x10E6/uL	4.14 - 5.80	01
Hemoglobin	15.8		g/dL	13.0 - 17.7	01
Hematocrit	47.5		%	37.5 - 51.0	01
MCV	92		fL	79 - 97	01
MCH	30.6		pg	26.6 - 33.0	01
MCHC	33.3		g/dL	31.5 - 35.7	01
RDW	14.0		%	12.3 - 15.4	01
Platelets	216		x10E3/uL	150 - 379	01
Neutrophils	55		%	Not Estab.	01
Lymphs	29		%	Not Estab.	01
Monocytes	10		%	Not Estab.	01
Eos	5		%	Not Estab.	01
Basos	1		%	Not Estab.	01
Neutrophils (Absolute)	2.3		x10E3/uL	1.4 - 7.0	01
Lymphs (Absolute)	1.2		x10E3/uL	0.7 - 3.1	01
Monocytes(Absolute)	0.4		x10E3/uL	0.1 - 0.9	01
Eos (Absolute)	0.2		x10E3/uL	0.0 - 0.4	01
Baso (Absolute)	0.1		x10E3/uL	0.0 - 0.2	01
Immature Granulocytes	0		%	Not Estab.	01
Immature Grans (Abs)	0.0		x10E3/uL	0.0 - 0.1	01
Comp. Metabolic Panel (14)					
Glucose	87		mg/dL	65 - 99	01
BUN	13		mg/dL	6 - 24	01
Creatinine	1.02		mg/dL	0.76 - 1.27	01

Patient: [redacted]
DOB: 02/27/1978
Patient ID: DL 17894
Control ID: B0082220747
Specimen ID: 297-298-1445-0
Date collected: 10/24/2018 0918 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
eGFR If NonAfricn Am	92		mL/min/1.73	>59	
eGFR If Africn Am	106		mL/min/1.73	>59	
BUN/Creatinine Ratio	13			9 - 20	
Sodium	139		mmol/L	134 - 144	01
Potassium	4.5		mmol/L	3.5 - 5.2	01
Chloride	100		mmol/L	96 - 106	01
Carbon Dioxide, Total	23		mmol/L	20 - 29	01
Calcium	9.5		mg/dL	8.7 - 10.2	01
Protein, Total	6.2		g/dL	6.0 - 8.5	01
Albumin	4.1		g/dL	3.5 - 5.5	01
Globulin, Total	2.1		g/dL	1.5 - 4.5	
A/G Ratio	2.0			1.2 - 2.2	
Bilirubin, Total	0.6		mg/dL	0.0 - 1.2	01
Alkaline Phosphatase	48		IU/L	39 - 117	01
AST (SGOT)	**57**	**High**	IU/L	0 - 40	01
ALT (SGPT)	34		IU/L	0 - 44	01
Lipid Panel w/ Chol/HDL Ratio					
Cholesterol, Total	148		mg/dL	100 - 199	01
Triglycerides	54		mg/dL	0 - 149	01
HDL Cholesterol	53		mg/dL	>39	01
VLDL Cholesterol Cal	11		mg/dL	5 - 40	
LDL Cholesterol Calc	84		mg/dL	0 - 99	
T. Chol/HDL Ratio	2.8		ratio	0.0 - 5.0	
Please Note:					01

T. Chol/HDL Ratio

	Men	Women
1/2 Avg.Risk	3.4	3.3
Avg.Risk	5.0	4.4
2X Avg.Risk	9.6	7.1
3X Avg.Risk	23.4	11.0

Testosterone, Free+Total LC/MS					
Testosterone, Total, LC/MS	**1018.1**	**High**	ng/dL	264.0 - 916.0	02
This LabCorp LC/MS-MS method is currently certified by the CDC Hormone Standardization Program (HoSt). Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.					
Disclaimer:					02
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.					
Free Testosterone(Direct)	21.1		pg/mL	6.8 - 21.5	02
Dihydrotestosterone	**117**	**High**	ng/dL		03

Patient [redacted]
DOB: 02/27/1978 Patient ID: DL 17894 Control ID: B0082220747
Specimen ID: 297-298-1445-0
Date collected: 10/24/2018 0918 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
Reference Range: **Adult Male: 30 - 85**					
Thyroxine (T4) Free, Direct, S					
T4,Free(Direct)	1.50		ng/dL	0.82 - 1.77	01
DHEA-Sulfate	127.0		ug/dL	102.6 - 416.3	01
TSH	1.680		uIU/mL	0.450 - 4.500	01
Prolactin	9.3		ng/mL	4.0 - 15.2	01
Prostate-Specific Ag, Serum					
Prostate Specific Ag, Serum	1.7		ng/mL	0.0 - 4.0	01
Roche ECLIA methodology. According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.					
IGF-1					
Insulin-Like Growth Factor I	**250**	**High**	ng/mL	83 - 233	02
Estradiol, Sensitive	13.9		pg/mL	8.0 - 35.0	02
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared by the Food and Drug Administration. Methodology: Liquid chromatography tandem mass spectrometry(LC/MS/MS)					
Triiodothyronine (T3), Free	3.6		pg/mL	2.0 - 4.4	01
Sex Horm Binding Glob, Serum	42.8		nmol/L	16.5 - 55.9	01

01	DA	LabCorp Dallas 7777 Forest Ln Bldg C350, Dallas, TX 75230-2544	Dir: CN Etufugh, MD
02	BN	LabCorp Burlington 1447 York Court, Burlington, NC 27215-3361	Dir: William F Hancock, MD
03	ES	Esoterix Inc 4301 Lost Hills Road, Calabasas Hills, CA 91301-5358	Dir: Samuel Pepkowitz, MD

For inquiries, the physician may contact **Branch: 800-877-5227 Lab: 972-598-6000**